Developer docs
API playgroundTry for free, no card

Search company profiles

Persista Bio

Full company profile

uuid00vkvld

Namestring
Persista Bio
Legal namestring
Persista Bio Inc.
Websiteurl
persistabio.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Persista Bio Inc. is a seed-stage biotherapeutics company developing implantable cell therapies to treat Type 1 diabetes and other chronic diseases. Founded in 2024 and headquartered in Ithaca, NY, the company is targeting the more than 9 million people worldwide living with Type 1 diabetes who currently require lifelong insulin management, with planned future applications across inflammation, pain, obesity, enzyme deficiencies, and metabolic disorders. The firm licenses two foundational technologies — an anti-fibrotic macroencapsulation capsule developed at Cornell University and an implantable electrochemical oxygen generator (iEOG) from Giner, Inc. — and combines them into its core product, the O2Line™ Oxygenated Cell Therapy Platform.

The O2Line™ system integrates a core-shell nanofibrous encapsulation capsule designed to prevent immune rejection and fibrotic scarring with an in-situ oxygen generator that uses electrolysis of tissue moisture to continuously supply oxygen to densely packed, insulin-secreting cells. According to the company, O2Line™ is the first system capable of fully supporting the viability and function of densely packed insulin-secreting cells in a subcutaneous, retrievable format, enabling self-regulating glucose response without daily injections, pumps, finger sticks, or sensors and without immunosuppression. Preclinical studies in diabetic rats demonstrated normalization of blood glucose for 90-120 days without immunosuppression; the work has been published on bioRxiv (May 2025) and in Nature Communications (August 2025).

Persista Bio is pre-clinical and pre-revenue with no commercial products on the market. The forward business model contemplates future revenue through sale of cell therapy implants and licensing of platform technology to biopharma and stem-cell partners. Current capital sources include a $2.1 million Direct-to-Phase II SBIR grant from NIDDK, a Phase I NIH manufacturing-readiness award (both announced September 2025), supplemental research support from the Hartwell Foundation, Breakthrough T1D, and Novo Nordisk Company, and a $3.5 million seed round currently in process. Go-to-market is centered on early partnerships with stem cell providers and biopharma collaborators; no pricing has been disclosed. Founding leadership comprises CEO Linda Tempelman (formerly Founding CEO of Giner Life Sciences), Cornell Professor Minglin Ma, and Cornell Professor Emeritus James Flanders, with an advisory board that includes Dr. James Shapiro, a recognized leader in islet transplantation.

Short descriptiontext

Persista Bio is a seed-stage biotech developing the O2Line™ oxygenated cell therapy platform, which pairs an anti-fibrotic macroencapsulation capsule with an implantable oxygen generator to deliver long-term, immunosuppression-free treatment for Type 1 diabetes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersIthaca, United States
HQ citystring
Ithaca
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable cell therapy, cell encapsulation technology, type 1 diabetes, biotherapeutics platform, medical device manufacturing
Industry2 codes
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Implantable Cell Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Cell Therapy Platform (Pre-revenue)
TypeHardware Sales
Description

Persista Bio is a seed stage, pre-clinical biotherapeutics company. No commercial revenue has been generated. The company is developing its O2Line™ Oxygenated Cell Therapy Platform for Type 1 diabetes and other chronic diseases. Future revenue model will likely involve sale of cell therapy implants and licensing of platform technology.

persistabio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1O2Line™
Description

The O2Line™ Cell Delivery System is an oxygenated encapsulation system for insulin-secreting stem cells. It combines implantable oxygenation technology with macroencapsulation to enable long-term, immunosuppression-free cell therapy for Type 1 diabetes.

persistabio.com
Core offering1 text field

Persista Bio is developing the O2Line™ Oxygenated Cell Therapy Platform, a long-term implantable cell therapy system for Type 1 diabetes and other chronic diseases. The platform combines an implantable electrochemical oxygen generator (iEOG) with a macroencapsulation cell capsule to deliver continuous oxygen to densely packed, insulin-secreting cells without requiring immunosuppression. The product is in preclinical development and has not yet been commercialized.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Normalized blood glucose for 90 days in diabetic rats during preclinical testing
+3 more records
Product overview1 text field

Persista Bio offers the O2Line™ Oxygenated Cell Therapy Platform as its core product. This system combines two main technology components: (1) an anti-fibrotic cell capsule licensed from Cornell University that protects implanted cells from immune rejection while allowing nutrient and therapeutic exchange, and (2) an implantable electrochemical oxygen generator (iEOG) licensed from Giner, Inc. that provides continuous oxygenation to support densely packed cells. The platform is designed initially for Type 1 diabetes treatment, with potential applications for other chronic diseases including inflammation, obesity, enzyme deficiencies, and metabolic disorders.

Product and service1 record
1O2Line™ Oxygenated Cell Therapy Platform
CategoryImplantable Cell Therapy Platform
Description

An implantable cell therapy platform that combines an anti-fibrotic macroencapsulation capsule with an in-situ electrochemical oxygen generator to deliver continuous oxygenation to densely packed insulin-secreting cells. Designed for long-term, immunosuppression-free treatment of Type 1 diabetes and other chronic diseases; preclinical stage with no commercial revenue.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or Integration
Description

Licensing macroencapsulation technology developed at Cornell University for cell delivery systems. Founding team includes Cornell professors. Research conducted at Minglin Ma Lab in the Department of Biological and Environmental Engineering.

Strategic tierCoreTypeTechnology or Integration
Description

Licensing implantable electrochemical oxygen generator (iEOG) technology from Giner, Inc. CEO Linda Tempelman previously served as Founding CEO of Giner Life Sciences. Giner Labs develops electrolyzer and fuel cell technologies with applications including life sciences and NASA/US Navy.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Preclinical-to-clinical stage company developing stem cell-derived islet therapies (Sertolin) for Type 1 diabetes, with emphasis on scalable GMP manufacturing of encapsulated cell products. Comparable emerging peer in the stem-cell-derived T1D space with similar long-term ambitions.

TypeBroad incumbent
Description

Major diabetes incumbent (Humalog, Trulicity, Mounjaro) with strategic cell therapy exposure through the acquisition of Sigilon Therapeutics in 2023. Lilly is pursuing encapsulated cell therapy for T1D and represents both a competitive incumbent and a likely strategic partner for any successful T1D cell therapy platform.

TypeDirect peer
Description

Developing the Cell Pouch System, an implantable subcutaneous device for therapeutic cell delivery (initially islets for T1D, now expanding into stem cell-derived cells). Sernova is one of the closest direct competitors in the encapsulated/implantable cell therapy space, with clinical-stage assets.

4ViaCyte
TypeDirect peer
Description

Pioneer in encapsulated stem cell-derived beta cell therapies for Type 1 diabetes (PEC-Direct, PEC-QT programs). Acquired by Vertex Pharmaceuticals in 2022, but operated as the most directly comparable encapsulated cell therapy peer to Persista Bio prior to the acquisition. Both target immunosuppression-free T1D treatment via macroencapsulation.

TypeEmerging player
Description

Developing a bio-artificial pancreas (Betalin Pancreas) using microencapsulation of insulin-secreting cells for Type 1 diabetes. Comparable emerging peer focused on encapsulated cell implants that remove the need for immunosuppression—a directly parallel design philosophy to Persista Bio's O2Line™.

6Sigilon Therapeutics
TypeDirect peer
Description

Developed Afibromer™-encapsulated cell therapies (including for Type 1 diabetes) using a sphere-encapsulation platform to avoid immunosuppression. Acquired by Eli Lilly in 2023 but had been one of the most directly comparable peers in encapsulated cell therapy design and T1D application.

TypeBroad incumbent
Description

Global insulin and T1D therapeutics leader, with growing investment in stem cell-derived therapies and cell encapsulation. Already a research supporter of Persista Bio. Represents both a strategic incumbent and a potential commercial partner/acquirer given its dominant T1D commercial footprint.

TypeBroad incumbent
Description

Acquired ViaCyte and is advancing VX-880 (stem cell-derived islets) and VX-264 (encapsulated version) in clinical trials for T1D. As the clinical-stage leader in stem cell diabetes therapy, Vertex represents both the most relevant benchmark and the most serious competitive threat to Persista Bio's eventual market entry.

TypeOthers
Description

Developer of electrolyzer and fuel cell technologies, including the implantable electrochemical oxygen generator (iEOG) licensed to Persista Bio. While primarily an enabling technology licensor rather than a competitor, Giner is a critical infrastructure partner and comparable in adjacent electrochemical medical device development.

10Procyon Technologies
TypeEmerging player
Description

Preclinical-stage biotech developing an oxygen-generating implantable cell therapy platform (similar in concept to Persista Bio's iEOG-based system) for diabetes and other endocrine disorders. Directly relevant emerging peer exploring oxygenation-enabled cell encapsulation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Persista Bio

Implantable Cell Therapypersistabio.com

Persista Bio is a seed-stage biotech developing the O2Line™ oxygenated cell therapy platform, which pairs an anti-fibrotic macroencapsulation capsule with an implantable oxygen generator to deliver long-term, immunosuppression-free treatment for Type 1 diabetes.

What Persista Bio does

Persista Bio Inc. is a seed-stage biotherapeutics company developing implantable cell therapies to treat Type 1 diabetes and other chronic diseases. Founded in 2024 and headquartered in Ithaca, NY, the company is targeting the more than 9 million people worldwide living with Type 1 diabetes who currently require lifelong insulin management, with planned future applications across inflammation, pain, obesity, enzyme deficiencies, and metabolic disorders. The firm licenses two foundational technologies — an anti-fibrotic macroencapsulation capsule developed at Cornell University and an implantable electrochemical oxygen generator (iEOG) from Giner, Inc. — and combines them into its core product, the O2Line™ Oxygenated Cell Therapy Platform.

The O2Line™ system integrates a core-shell nanofibrous encapsulation capsule designed to prevent immune rejection and fibrotic scarring with an in-situ oxygen generator that uses electrolysis of tissue moisture to continuously supply oxygen to densely packed, insulin-secreting cells. According to the company, O2Line™ is the first system capable of fully supporting the viability and function of densely packed insulin-secreting cells in a subcutaneous, retrievable format, enabling self-regulating glucose response without daily injections, pumps, finger sticks, or sensors and without immunosuppression. Preclinical studies in diabetic rats demonstrated normalization of blood glucose for 90-120 days without immunosuppression; the work has been published on bioRxiv (May 2025) and in Nature Communications (August 2025).

Persista Bio is pre-clinical and pre-revenue with no commercial products on the market. The forward business model contemplates future revenue through sale of cell therapy implants and licensing of platform technology to biopharma and stem-cell partners. Current capital sources include a $2.1 million Direct-to-Phase II SBIR grant from NIDDK, a Phase I NIH manufacturing-readiness award (both announced September 2025), supplemental research support from the Hartwell Foundation, Breakthrough T1D, and Novo Nordisk Company, and a $3.5 million seed round currently in process. Go-to-market is centered on early partnerships with stem cell providers and biopharma collaborators; no pricing has been disclosed. Founding leadership comprises CEO Linda Tempelman (formerly Founding CEO of Giner Life Sciences), Cornell Professor Minglin Ma, and Cornell Professor Emeritus James Flanders, with an advisory board that includes Dr. James Shapiro, a recognized leader in islet transplantation.

Persista Bio firmographics

Firmographics
Name
Persista Bio
Legal name
Persista Bio Inc.
Website
https://persistabio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Persista Bio is a seed-stage biotech developing the O2Line™ oxygenated cell therapy platform, which pairs an anti-fibrotic macroencapsulation capsule with an implantable oxygen generator to deliver long-term, immunosuppression-free treatment for Type 1 diabetes.
Ownership category
akta.pro rank

Persista Bio industry classification

Industry
Product category
Implantable Cell Therapy
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAAAO
Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Implantable cell therapy
  • Cell encapsulation technology
  • Type 1 diabetes
  • Biotherapeutics platform
  • Medical device manufacturing

Where Persista Bio is headquartered

Location

Headquarters

HQ city
Ithaca
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Persista Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Cell Therapy Platform (Pre-revenue): Persista Bio is a seed stage, pre-clinical biotherapeutics company. No commercial revenue has been generated. The company is developing its O2Line™ Oxygenated Cell Therapy Platform for Type 1 diabetes and other chronic diseases. Future revenue model will likely involve sale of cell therapy implants and licensing of platform technology.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Persista Bio product offering

Product offering

Core offering

Persista Bio is developing the O2Line™ Oxygenated Cell Therapy Platform, a long-term implantable cell therapy system for Type 1 diabetes and other chronic diseases. The platform combines an implantable electrochemical oxygen generator (iEOG) with a macroencapsulation cell capsule to deliver continuous oxygen to densely packed, insulin-secreting cells without requiring immunosuppression. The product is in preclinical development and has not yet been commercialized.

Product overview

Persista Bio offers the O2Line™ Oxygenated Cell Therapy Platform as its core product. This system combines two main technology components: (1) an anti-fibrotic cell capsule licensed from Cornell University that protects implanted cells from immune rejection while allowing nutrient and therapeutic exchange, and (2) an implantable electrochemical oxygen generator (iEOG) licensed from Giner, Inc. that provides continuous oxygenation to support densely packed cells. The platform is designed initially for Type 1 diabetes treatment, with potential applications for other chronic diseases including inflammation, obesity, enzyme deficiencies, and metabolic disorders.

Differentiator

Problem solved

Functional benefit

Brands

  • O2Line™: The O2Line™ Cell Delivery System is an oxygenated encapsulation system for insulin-secreting stem cells. It combines implantable oxygenation technology with macroencapsulation to enable long-term, immunosuppression-free cell therapy for Type 1 diabetes.

Products and services

  • O2Line™ Oxygenated Cell Therapy Platform An implantable cell therapy platform that combines an anti-fibrotic macroencapsulation capsule with an in-situ electrochemical oxygen generator to deliver continuous oxygenation to densely packed insulin-secreting cells. Designed for long-term, immunosuppression-free treatment of Type 1 diabetes and other chronic diseases; preclinical stage with no commercial revenue.

Quantifiable outcome

  • Normalized blood glucose for 90 days in diabetic rats during preclinical testing
  • +3 more outcomes

Companies that use Persista Bio

Customer profile

Segments2 records

Ideal customer profiles2 records

Persista Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Persista Bio partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Cornell UniversitycoreTechnology or IntegrationLicensing macroencapsulation technology developed at Cornell University for cell delivery systems. Founding team includes Cornell professors. Research conducted at Minglin Ma Lab in the Department of Biological and Environmental Engineering.
  • Giner, Inc. (Giner Labs)coreTechnology or IntegrationLicensing implantable electrochemical oxygen generator (iEOG) technology from Giner, Inc. CEO Linda Tempelman previously served as Founding CEO of Giner Life Sciences. Giner Labs develops electrolyzer and fuel cell technologies with applications including life sciences and NASA/US Navy.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Persista Bio competitors and assessment

Company assessment

Emerging players

  • Seraxis: Preclinical-to-clinical stage company developing stem cell-derived islet therapies (Sertolin) for Type 1 diabetes, with emphasis on scalable GMP manufacturing of encapsulated cell products. Comparable emerging peer in the stem-cell-derived T1D space with similar long-term ambitions.
  • Betalin Therapeutics: Developing a bio-artificial pancreas (Betalin Pancreas) using microencapsulation of insulin-secreting cells for Type 1 diabetes. Comparable emerging peer focused on encapsulated cell implants that remove the need for immunosuppression—a directly parallel design philosophy to Persista Bio's O2Line™.
  • Procyon Technologies: Preclinical-stage biotech developing an oxygen-generating implantable cell therapy platform (similar in concept to Persista Bio's iEOG-based system) for diabetes and other endocrine disorders. Directly relevant emerging peer exploring oxygenation-enabled cell encapsulation.

Broad incumbents

  • Eli Lilly: Major diabetes incumbent (Humalog, Trulicity, Mounjaro) with strategic cell therapy exposure through the acquisition of Sigilon Therapeutics in 2023. Lilly is pursuing encapsulated cell therapy for T1D and represents both a competitive incumbent and a likely strategic partner for any successful T1D cell therapy platform.
  • Novo Nordisk: Global insulin and T1D therapeutics leader, with growing investment in stem cell-derived therapies and cell encapsulation. Already a research supporter of Persista Bio. Represents both a strategic incumbent and a potential commercial partner/acquirer given its dominant T1D commercial footprint.
  • Vertex Pharmaceuticals: Acquired ViaCyte and is advancing VX-880 (stem cell-derived islets) and VX-264 (encapsulated version) in clinical trials for T1D. As the clinical-stage leader in stem cell diabetes therapy, Vertex represents both the most relevant benchmark and the most serious competitive threat to Persista Bio's eventual market entry.

Direct peers

  • Sernova Corp: Developing the Cell Pouch System, an implantable subcutaneous device for therapeutic cell delivery (initially islets for T1D, now expanding into stem cell-derived cells). Sernova is one of the closest direct competitors in the encapsulated/implantable cell therapy space, with clinical-stage assets.
  • ViaCyte: Pioneer in encapsulated stem cell-derived beta cell therapies for Type 1 diabetes (PEC-Direct, PEC-QT programs). Acquired by Vertex Pharmaceuticals in 2022, but operated as the most directly comparable encapsulated cell therapy peer to Persista Bio prior to the acquisition. Both target immunosuppression-free T1D treatment via macroencapsulation.
  • Sigilon Therapeutics: Developed Afibromer™-encapsulated cell therapies (including for Type 1 diabetes) using a sphere-encapsulation platform to avoid immunosuppression. Acquired by Eli Lilly in 2023 but had been one of the most directly comparable peers in encapsulated cell therapy design and T1D application.

Others

  • Giner, Inc. Developer of electrolyzer and fuel cell technologies, including the implantable electrochemical oxygen generator (iEOG) licensed to Persista Bio. While primarily an enabling technology licensor rather than a competitor, Giner is a critical infrastructure partner and comparable in adjacent electrochemical medical device development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Persista Bio social profiles

Digital presence

Persista Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Persista Bio leadership team

Management profile

Number of profiles

Profiles3 records

Persista Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Persista Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Persista Bio

What does Persista Bio do?

Persista Bio is developing the O2Line™ Oxygenated Cell Therapy Platform, a long-term implantable cell therapy system for Type 1 diabetes and other chronic diseases. The platform combines an implantable electrochemical oxygen generator (iEOG) with a macroencapsulation cell capsule to deliver continuous oxygen to densely packed, insulin-secreting cells without requiring immunosuppression. The product is in preclinical development and has not yet been commercialized.

Is Persista Bio a public or private company?

Persista Bio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Persista Bio founded?

Persista Bio was founded in 2024. It employs 1 to 10 people.

Where is Persista Bio based?

Persista Bio is headquartered in Ithaca, United States, in the North America region.

How does Persista Bio make money?

One revenue line is on record: cell Therapy Platform (Pre-revenue).

Who are Persista Bio's main competitors?

Emerging players on record are Seraxis, Betalin Therapeutics and Procyon Technologies. Broad incumbents are Eli Lilly, Novo Nordisk and Vertex Pharmaceuticals. Direct peers are Sernova Corp, ViaCyte and Sigilon Therapeutics. Giner, Inc. is listed as an others.

Does Persista Bio have an API?

No public API is recorded for Persista Bio.

What industry is Persista Bio in?

Persista Bio's product category is Implantable Cell Therapy. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAIAAAO, Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales